Taneli Jouhikainen
Director/Board Member chez Mirror Biologics Inc
Profil
Taneli Jouhikainen was the founder of Aravas, Inc. founded in 2007 where he held the title of Chief Operating Officer from 2009 to 2014.
He is currently a Director at Mirror Biologics Inc. Dr. Jouhikainen's former positions include President & Chief Executive Officer at AKELA Pharma Oy from 2001 to 2004, Chief Executive Officer at Akela Pharma, Inc. in 2009, Head-Clinical Research at Bayer Schering Pharma AG from 1994 to 2000, Head-Drug Development Business Unit at LAB International, Inc. from 2004 to 2006, Head-Clinical Development at Leiras, President & Chief Business Officer at Savara, Inc. from 2017 to 2020.
He was also the Chief Operating Officer at RELIEF THERAPEUTICS Holding SA from 2021 to 2022.
Dr. Jouhikainen holds a doctorate from the University of Helsinki and an MBA from Aalto University School of Business.
Postes actifs de Taneli Jouhikainen
Sociétés | Poste | Début |
---|---|---|
Mirror Biologics Inc
Mirror Biologics Inc BiotechnologyHealth Technology Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019. | Director/Board Member | - |
Anciens postes connus de Taneli Jouhikainen
Sociétés | Poste | Fin |
---|---|---|
RELIEF THERAPEUTICS HOLDING SA | Chief Operating Officer | 14/10/2022 |
SAVARA INC. | President | 11/09/2020 |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Chief Executive Officer | 02/09/2009 |
LAB International, Inc.
LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | Corporate Officer/Principal | 01/09/2006 |
AKELA Pharma Oy
AKELA Pharma Oy Pharmaceuticals: OtherHealth Technology AKELA Pharma Oy, founded in 2000, develops inhalers, inhalation products, and related production technology. The company is based in Turku, Finland. AKELA Pharma was acquired by LAB International, Inc. on January 12, 2004 for $1.85 million. | Chief Executive Officer | 01/01/2004 |
Formation de Taneli Jouhikainen
University of Helsinki | Doctorate Degree |
Aalto University School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
RELIEF THERAPEUTICS HOLDING SA | Health Technology |
SAVARA INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Bayer Schering Pharma AG | Health Technology |
LAB International, Inc.
LAB International, Inc. Pharmaceuticals: MajorHealth Technology LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies | Health Technology |
Aravas, Inc.
Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Health Technology |
AKELA Pharma Oy
AKELA Pharma Oy Pharmaceuticals: OtherHealth Technology AKELA Pharma Oy, founded in 2000, develops inhalers, inhalation products, and related production technology. The company is based in Turku, Finland. AKELA Pharma was acquired by LAB International, Inc. on January 12, 2004 for $1.85 million. | Health Technology |
Leiras
Leiras Pharmaceuticals: OtherHealth Technology Part of Bayer AG, Leiras is a Finnish company that specializes in medicinal chemicals and botanical products. The private company is located in Finland. Leiras was acquired by Bayer Schering Pharma AG on July 01, 1996 for $262.11 million. | Health Technology |
Akela Pharma, Inc.
Akela Pharma, Inc. Pharmaceuticals: MajorHealth Technology Akela Pharma, Inc. operates as a drug development company, which develops and manufactures pharmaceutical formulations and drugs. The company operates as a specialty contract pharmaceutical formulation developer and clinical and commercial drug manufacturer for proprietary drug products through its wholly-owned subsidiary, PharmaForm LLC, a pharmaceutical intellectual property development company. It provides specialty contract services in the area of pharmaceutical dosage form development, preclinical, scale-up, clinical and commercial supply manufacturing, focusing on controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying and liquid filled capsules. Akela Pharma was founded on November 15, 1988 and is headquartered in Austin, TX. | Health Technology |
Mirror Biologics Inc
Mirror Biologics Inc BiotechnologyHealth Technology Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019. | Health Technology |